We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Efalizumab-Associated Guillain-Barré Syndrome

Frank Victor, MD; Kavita Menon, MD; Jo-Ann M. Latkowski, MD; Adolfo Fernandez-Obregon, MD; Bruce E. Strober, MD, PhD
Arch Dermatol. 2008;144(10):1396-1397. doi:10.1001/archderm.144.10.1396.
Text Size: A A A
Published online


We report a case of Guillain-Barré syndrome associated with efalizumab therapy for chronic plaque psoriasis.

Mohan  NEdward  ETCupps  TR  et al.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44 (12) 2862- 2869
PubMed Link to Article[[XSLOpenURL/10.1002/(ISSN)1529-0131]]
Shin  ISBaer  ANKwon  HJ  et al.  Guillain-Barre and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum 2006;54 (5) 1429- 1434
PubMed Link to Article[[XSLOpenURL/10.1002/(ISSN)1529-0131]]
Magnano  MDRobinson  WHGenovese  MC Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol 2004;22 (5) ((suppl 35)) S134- S140
 Raptiva (efalizumab) [package insert].  South San Francisco, CA Genentech Inc2005;
European Medicines Agency, Procedural steps taken and scientific information after the authorisation: Raptiva. http://www.emea.europa.eu/humandocs/Humans/EPAR/raptiva/raptiva.htm. Accessed September 20, 2007

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

6 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles